Literature DB >> 1373502

Role and regulation of interleukin (IL)-2 receptor alpha and beta chains in IL-2-driven B-cell growth.

K Nakanishi1, S Hirose, T Yoshimoto, H Ishizashi, K Hiroishi, T Tanaka, T Kono, M Miyasaka, T Taniguchi, K Higashino.   

Abstract

Substantial proportions of resting B cells constitutively express low levels of IL-2 receptor (IL-2R) alpha and/or beta chains. The expression of these chains is differentially regulated by anti-IgM and IL-2/IL-4. The anti-IgM induces IL-2R alpha chain expression, whereas each of the two cytokines induces IL-2R beta chain expression in a dose-dependent manner. Moreover, IL-2 induces the growth of B cells, when the cells were pretreated with IL-2 or IL-4 for 24 h. The magnitude of this IL-2-driven B-cell growth depends upon the level of IL-2R beta chain expression. Costimulation of the B cells with IL-2 and anti-IgM shifts the dose-response curve, and the cells proliferate at an IL-2 concentration as low as 40 pM. These results indicate that the levels of anti-IgM-induced IL-2R alpha chain and IL-2-induced IL-2R beta chain determine the sensitivity of the cells to IL-2.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1373502      PMCID: PMC48906          DOI: 10.1073/pnas.89.8.3551

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Lymphokine-regulated differential expression of mRNA for p75kDa-IL-2R and p55kDa-IL-2R in a cloned B lymphoma line (BLC1-CL-3 cells).

Authors:  K Nakanishi; K Matsui; S Hirose; T Yoshimoto; K Hiroishi; T Kono; T Hada; T Hamaoka; K Higashino
Journal:  J Immunol       Date:  1990-09-01       Impact factor: 5.422

2.  The murine IL 2 receptor. I. Monoclonal antibodies that define distinct functional epitopes on activated T cells and react with activated B cells.

Authors:  G Ortega; R J Robb; E M Shevach; T R Malek
Journal:  J Immunol       Date:  1984-10       Impact factor: 5.422

3.  A second human interleukin-2 binding protein that may be a component of high-affinity interleukin-2 receptors.

Authors:  M Dukovich; Y Wano; P Katz; B R Cullen; J H Kehrl; W C Greene
Journal:  Nature       Date:  1987 Jun 11-17       Impact factor: 49.962

Review 4.  Interleukin-2: inception, impact, and implications.

Authors:  K A Smith
Journal:  Science       Date:  1988-05-27       Impact factor: 47.728

5.  Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen.

Authors:  R J Robb; W C Greene; C M Rusk
Journal:  J Exp Med       Date:  1984-10-01       Impact factor: 14.307

6.  A novel monoclonal antibody against murine IL-2 receptor beta-chain. Characterization of receptor expression in normal lymphoid cells and EL-4 cells.

Authors:  T Tanaka; M Tsudo; H Karasuyama; F Kitamura; T Kono; M Hatakeyama; T Taniguchi; M Miyasaka
Journal:  J Immunol       Date:  1991-10-01       Impact factor: 5.422

7.  Nucleotide sequence and expression of a mouse interleukin 2 receptor cDNA.

Authors:  J Miller; T R Malek; W J Leonard; W C Greene; E M Shevach; R N Germain
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

8.  Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors.

Authors:  M A Caligiuri; A Zmuidzinas; T J Manley; H Levine; K A Smith; J Ritz
Journal:  J Exp Med       Date:  1990-05-01       Impact factor: 14.307

9.  Activated B cells express receptors for, and proliferate in response to, pure interleukin 2.

Authors:  R H Zubler; J W Lowenthal; F Erard; N Hashimoto; R Devos; H R MacDonald
Journal:  J Exp Med       Date:  1984-10-01       Impact factor: 14.307

10.  B cell helper factors. I. Requirement for both interleukin 2 and another 40,000 mol wt factor.

Authors:  H J Leibson; P Marrack; J W Kappler
Journal:  J Exp Med       Date:  1981-11-01       Impact factor: 14.307

View more
  8 in total

1.  Anti-CD25 antibody treatment of mice vaccinated and challenged with Borrelia spp. does not exacerbate arthritis but inhibits borreliacidal antibody production.

Authors:  Dean T Nardelli; Thomas F Warner; Steven M Callister; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2006-08

2.  Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-gamma production from activated B cells.

Authors:  T Yoshimoto; H Okamura; Y I Tagawa; Y Iwakura; K Nakanishi
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

3.  The acquisition of cytokine responsiveness by murine B cells: a role for antigen and IL-5 in the induction of IL-2 receptors.

Authors:  J Poudrier; T Owens
Journal:  Immunology       Date:  1994-03       Impact factor: 7.397

Review 4.  Anti-viral CD8 T cells and the cytokines that they love.

Authors:  Maureen A Cox; Shannon M Kahan; Allan J Zajac
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

5.  Late expression of granulysin by microbicidal CD4+ T cells requires PI3K- and STAT5-dependent expression of IL-2Rbeta that is defective in HIV-infected patients.

Authors:  Chun Fu Zheng; Gareth J Jones; Meiqing Shi; Jeremy C D Wiseman; Kaleb J Marr; Byron M Berenger; Shaunna M Huston; M John Gill; Alan M Krensky; Paul Kubes; Christopher H Mody
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

6.  Differential effects of interleukin-2 and interleukin-4 on immunomodulatory role of platelet-activating factor in human B cells.

Authors:  C L Patke; C G Green; W T Shearer
Journal:  Clin Diagn Lab Immunol       Date:  1994-07

7.  Characterization of the human interleukin-2 receptor beta-chain gene promoter: regulation of promoter activity by ets gene products.

Authors:  J X Lin; N K Bhat; S John; W S Queale; W J Leonard
Journal:  Mol Cell Biol       Date:  1993-10       Impact factor: 4.272

8.  The role of endogenous interleukin-2 in proliferation of human carcinoma cell lines.

Authors:  T E Reichert; Y Kashii; J Stanson; A Zeevi; T L Whiteside
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.